Theralase Technologies Inc. (TLTFF)
| Previous Close | 0.1158 |
| Open | 0.1148 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.1148 - 0.1205 |
| 52 Week Range | 0.1100 - 0.2400 |
| Volume | |
| Avg. Volume | 77,909 |
| Market Cap | 28.835M |
| Beta (5Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | May 28, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIRETheralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo ...
- ACCESSWIRE
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase® " or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation ...
- ACCESSWIRE
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated ...
